We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization.
- Authors
Mansour, Ahmad M.; Mackensen, Friederike; Mahendradas, Padmamalini; Khairallah, Moncef; Lai, Timothy Y. Y.; Bashshur, Ziad
- Abstract
Purpose: To assess the 5-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization. Methods: Retrospective, multicenter, consecutive case series of eight patients with inflammatory ocular neovascularization refractory to standard therapy who were treated with intravitreal bevacizumab and followed for 5 years after first injection. The outcome measures included improvement of best-corrected visual acuity expressed as logarithm of minimum angle of resolution. Results: Mean best-corrected visual acuity significantly improved from 0.58 at baseline (6/23 or 20/76; standard deviation = 0.32) to 0.20 at final assessment (6/10 or 20/32; standard deviation = 0.25) (n = 8; P = 0.02), a gain of 3.8 lines (median: three injections; eight eyes; eight patients). No ocular or systemic complications from intravitreal bevacizumab were noted. Conclusion: At 5 years, intravitreal bevacizumab sustained significant visual improvement in ocular neovascularization due to a variety of inflammatory ocular diseases without major complications after a median of three injections.
- Subjects
BEVACIZUMAB; ANTINEOPLASTIC agents; NEOVASCULARIZATION; BLOOD-vessel development; INFLAMMATION
- Publication
Clinical Ophthalmology, 2012, Vol 6, p1233
- ISSN
1177-5467
- Publication type
Article
- DOI
10.2147/OPTH.S34294